In the latest session, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed at $48.51 down -4.00% from its previous closing price of $50.53. In other words, the price has decreased by -$2.02 from its previous closing price. On the day, 639243 shares were traded. RARE stock price reached its highest trading level at $50.95 during the session, while it also had its lowest trading level at $48.40.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 3.39 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $72.
Evercore ISI Upgraded its In-line to Outperform on June 06, 2023, whereas the target price for the stock was revised from $60 to $80.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 07 ’24 when Fust Matthew K sold 12,195 shares for $50.88 per share. The transaction valued at 620,443 led to the insider holds 14,860 shares of the business.
Harris Erik sold 4,768 shares of RARE for $256,328 on Mar 01 ’24. The EVP & Chief Commercial Officer now owns 67,163 shares after completing the transaction at $53.76 per share. On Mar 01 ’24, another insider, Pinion John Richard, who serves as the insider of the company, sold 4,173 shares for $53.76 each. As a result, the insider received 224,340 and left with 89,268 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4.16B and an Enterprise Value of 3.63B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.20 while its Price-to-Book (P/B) ratio in mrq is 14.50. Its current Enterprise Value per Revenue stands at 8.36 whereas that against EBITDA is -7.03.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is 47.33, while the 200-Day Moving Average is calculated to be 42.55.
Shares Statistics:
For the past three months, RARE has traded an average of 795.75K shares per day and 745.37k over the past ten days. A total of 82.32M shares are outstanding, with a floating share count of 77.00M. Insiders hold about 6.48% of the company’s shares, while institutions hold 104.72% stake in the company. Shares short for RARE as of Feb 15, 2024 were 3.56M with a Short Ratio of 4.47, compared to 4.12M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.32% and a Short% of Float of 4.50%.
Earnings Estimates
There are 16 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.76 for the current quarter, with a high estimate of -$1.39 and a low estimate of -$2.04, while EPS last year was -$2.33. The consensus estimate for the next quarter is -$1.63, with high estimates of -$1.36 and low estimates of -$2.01.
Analysts are recommending an EPS of between -$5.23 and -$8.12 for the fiscal current year, implying an average EPS of -$6.45. EPS for the following year is -$4.9, with 17 analysts recommending between -$1.58 and -$6.9.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $116.17M this quarter.It ranges from a high estimate of $124.6M to a low estimate of $98.8M. As of the current estimate, Ultragenyx Pharmaceutical Inc.’s year-ago sales were $100.5M, an estimated increase of 15.60% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $125.41M, an increase of 15.80% over than the figure of $15.60% in the same quarter last year. There is a high estimate of $130.1M for the next quarter, whereas the lowest estimate is $120.38M.
A total of 17 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $530.01M, while the lowest revenue estimate was $499.73M, resulting in an average revenue estimate of $513.09M. In the same quarter a year ago, actual revenue was $434.25M, up 18.20% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $649.05M in the next fiscal year. The high estimate is $920.7M and the low estimate is $541.73M. The average revenue growth estimate for next year is up 26.50% from the average revenue estimate for this year.
